Back
22 January 2020

[Infographic] Are Radiopharmaceuticals the New Hot Area in Biopharmaceuticals?

Written by Colin G. Miller

Radiopharmaceuticals are seeing a big increase in new deals and licensing agreements.  Ever since Novartis bought into the market by acquiring AAA in 2016, there has been a renewed interest in the diagnostic and therapeutic market with the FDA approving the first protein receptor radionuclide therapy (PRRT) with Lutathera for the treatment of neuroendocrine tumors.  In 2019 there were as many deals, agreements and approvals in the previous 3 years combined.  2020 has kicked off with Radiomedix/Curium announcing the new drug application (NDA) of 64Cu-Dotatate.  The Bracken Group continues to work in and monitor this developing field.

 

Radiopharmaceuticals_Market_Image-1

Download a PDF Version | Download the Image

We encourage you to share this image with colleagues, use it in PowerPoint slides, or post on LinkedIn.

 

New call-to-action

RECENT BLOG POST

6 Ways to Use Clinical Trial Condition Data for Life Science Sales

Life science sales teams know that data is essential to successful sales, but many of us could..

How Data Builds Trust in the Unique World of Life Science Sales

“Establishing trust is better than any sales technique.” – Mike Puglia   Many sales professionals..